Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$17.69
-0.4%
$18.18
$16.10
$42.47
$2.23B0.682.35 million shs2.09 million shs
BellRing Brands Inc. stock logo
BRBR
BellRing Brands
$58.77
-3.3%
$66.45
$48.06
$80.67
$7.72B0.741.41 million shs2.97 million shs
Haemonetics Corporation stock logo
HAE
Haemonetics
$71.20
+1.6%
$66.23
$55.30
$94.99
$3.37B0.36679,445 shs662,869 shs
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$91.98
-1.0%
$94.53
$80.98
$111.45
$5.49B0.66535,260 shs960,835 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
0.00%-7.79%-4.05%-26.43%-55.68%
BellRing Brands Inc. stock logo
BRBR
BellRing Brands
0.00%+1.19%-7.06%-14.08%+9.02%
Haemonetics Corporation stock logo
HAE
Haemonetics
0.00%-1.82%+1.51%+9.23%-18.04%
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
0.00%-0.66%-5.93%-8.59%+14.27%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
4.6977 of 5 stars
4.33.00.04.43.32.50.6
BellRing Brands Inc. stock logo
BRBR
BellRing Brands
4.1621 of 5 stars
4.45.00.00.02.22.51.3
Haemonetics Corporation stock logo
HAE
Haemonetics
4.3437 of 5 stars
3.41.00.04.32.01.72.5
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
4.0917 of 5 stars
3.51.00.03.82.22.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.62
Moderate Buy$40.05126.41% Upside
BellRing Brands Inc. stock logo
BRBR
BellRing Brands
2.81
Moderate Buy$77.0031.01% Upside
Haemonetics Corporation stock logo
HAE
Haemonetics
2.78
Moderate Buy$97.8937.49% Upside
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
3.00
Buy$109.1118.62% Upside

Current Analyst Ratings Breakdown

Latest BRBR, MMSI, APLS, and HAE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$26.00 ➝ $29.00
5/28/2025
BellRing Brands Inc. stock logo
BRBR
BellRing Brands
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$85.00 ➝ $75.00
5/27/2025
BellRing Brands Inc. stock logo
BRBR
BellRing Brands
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$85.00
5/23/2025
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$106.00 ➝ $110.00
5/22/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$49.00 ➝ $41.00
5/21/2025
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$108.00 ➝ $112.00
5/21/2025
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$106.00 ➝ $108.00
5/20/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$100.00 ➝ $100.00
5/15/2025
BellRing Brands Inc. stock logo
BRBR
BellRing Brands
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$85.00
5/15/2025
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$100.00 ➝ $108.00
5/14/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$30.00 ➝ $20.00
(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$781.37M2.85N/AN/A$1.84 per share9.61
BellRing Brands Inc. stock logo
BRBR
BellRing Brands
$2.00B3.74$2.19 per share26.80($1.60) per share-36.73
Haemonetics Corporation stock logo
HAE
Haemonetics
$1.36B2.51$7.32 per share9.72$16.34 per share4.36
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$1.36B4.01$5.55 per share16.58$23.67 per share3.89
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$197.88M-$1.79N/AN/AN/A-28.83%-99.19%-25.35%7/30/2025 (Estimated)
BellRing Brands Inc. stock logo
BRBR
BellRing Brands
$246.50M$2.1527.3423.141.9212.82%-133.63%32.69%8/4/2025 (Estimated)
Haemonetics Corporation stock logo
HAE
Haemonetics
$167.68M$3.3121.5114.131.1312.32%26.37%9.22%8/14/2025 (Estimated)
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$120.36M$2.0445.0924.533.068.81%15.52%8.72%7/30/2025 (Estimated)

Latest BRBR, MMSI, APLS, and HAE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q4 2025
Haemonetics Corporation stock logo
HAE
Haemonetics
$1.22$1.24+$0.02$1.17$329.38 million$330.60 million
5/7/2025Q1 2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$0.36-$0.74-$0.38-$0.74$197.61 million$149.90 million
5/5/2025Q2 2025
BellRing Brands Inc. stock logo
BRBR
BellRing Brands
$0.53$0.53N/A$0.45$577.56 million$588.00 million
4/24/2025Q1 2025
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$0.75$0.86+$0.11$0.49$352.57 million$355.35 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
N/AN/AN/AN/AN/A
BellRing Brands Inc. stock logo
BRBR
BellRing Brands
N/AN/AN/AN/AN/A
Haemonetics Corporation stock logo
HAE
Haemonetics
N/AN/AN/AN/AN/A
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.76
4.08
3.62
BellRing Brands Inc. stock logo
BRBR
BellRing Brands
N/A
2.92
1.34
Haemonetics Corporation stock logo
HAE
Haemonetics
1.12
1.62
0.99
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
0.51
4.87
3.26

Institutional Ownership

CompanyInstitutional Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
96.29%
BellRing Brands Inc. stock logo
BRBR
BellRing Brands
94.97%
Haemonetics Corporation stock logo
HAE
Haemonetics
99.67%
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
99.66%

Insider Ownership

CompanyInsider Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
6.50%
BellRing Brands Inc. stock logo
BRBR
BellRing Brands
1.07%
Haemonetics Corporation stock logo
HAE
Haemonetics
1.84%
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
3.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
770125.68 million117.51 millionOptionable
BellRing Brands Inc. stock logo
BRBR
BellRing Brands
380127.00 million125.64 millionOptionable
Haemonetics Corporation stock logo
HAE
Haemonetics
3,02348.04 million47.16 millionOptionable
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
7,40059.10 million57.21 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apellis Pharmaceuticals stock logo

Apellis Pharmaceuticals NASDAQ:APLS

$17.69 -0.07 (-0.39%)
Closing price 04:00 PM Eastern
Extended Trading
$17.68 -0.01 (-0.06%)
As of 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

BellRing Brands stock logo

BellRing Brands NYSE:BRBR

$58.77 -1.98 (-3.26%)
Closing price 03:59 PM Eastern
Extended Trading
$58.75 -0.02 (-0.04%)
As of 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BellRing Brands, Inc., together with its subsidiaries, provides various nutrition products in the United States. The company offers ready-to-drink (RTD) protein shakes, other RTD beverages, powders, nutrition bars, and other products primarily under the Premier Protein and Dymatize brands. It distributes its products through club, food, drug, mass, eCommerce, specialty, and convenience channels. BellRing Brands, Inc. was incorporated in 2019 and is headquartered in Saint Louis, Missouri.

Haemonetics stock logo

Haemonetics NYSE:HAE

$71.20 +1.14 (+1.62%)
Closing price 03:59 PM Eastern
Extended Trading
$70.10 -1.10 (-1.54%)
As of 06:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Merit Medical Systems stock logo

Merit Medical Systems NASDAQ:MMSI

$91.98 -0.97 (-1.04%)
Closing price 04:00 PM Eastern
Extended Trading
$91.95 -0.03 (-0.03%)
As of 05:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate structures; gastroenterology products, such as covered esophageal stents, syringe and gauges, and balloon dilators; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.